Market Research Report
Cystic Fibrosis (CF) - Epidemiology Forecast to 2030
|Cystic Fibrosis (CF) - Epidemiology Forecast to 2030|
Published: August 31, 2021
Content info: 41 Pages
Delivery time: 1-2 business days
Cystic fibrosis (CF) is a progressive, inherited disorder that primarily affects the respiratory and digestive systems. In people with CF, mucus, sweat, and other fluids produced in these systems are sticky and thick, and may obstruct the passageways in the lungs and pancreas (Mayo Clinic, 2021). Mucus build-up and airway blockages in the lungs cause symptoms such as persistent cough, wheezing, inflamed nasal passages, and recurrent lung infections. Impacts on the digestive system can lead to chronic constipation, intestinal blockages, and weight loss (Mayo Clinic, 2021).
GlobalData epidemiologists utilized comprehensive, country-specific data from national CF registries and peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the diagnosed prevalent cases of CF. For all the 7MM, CF cases were segmented by age, sex, mutation type, and MRSA infection. Finally, historical data were evaluated in all 7MM to strengthen the forecast by more accurately capturing changes in prevalence throughout the forecast period.
GlobalData epidemiologists forecast that the diagnosed prevalent cases of CF in the 7MM will grow by an annual growth rate (AGR) of 0.51% over the next 10 years, from 69,134 cases in 2020 to 72,659 cases in 2030. For CF mutation type in 2020, the F508del was the most prevalent gene mutation, representing 80.51% of diagnosed prevalent cases of CF in the 7MM. With the more widespread implementation of newborn screening programs, CF is now detected, and thus intervention can begin, earlier than ever. GlobalData epidemiologists expect that continued improvements in the treatment and care of CF patients may drive the number of diagnosed prevalent cases higher as people with CF live longer.
The CF Epidemiology series will allow you to -